Main public logs
Jump to navigation
Jump to search
Combined display of all available logs of wikidoc. You can narrow down the view by selecting a log type, the username (case-sensitive), or the affected page (also case-sensitive).
- 02:49, 2 June 2024 Kosar Doraghi talk contribs created page File:IMG 1227.jpeg
- 02:49, 2 June 2024 Kosar Doraghi talk contribs uploaded File:IMG 1227.jpeg
- 02:48, 2 June 2024 Kosar Doraghi talk contribs created page File:IMG 1236.jpeg
- 02:48, 2 June 2024 Kosar Doraghi talk contribs uploaded File:IMG 1236.jpeg
- 02:46, 2 June 2024 Kosar Doraghi talk contribs created page File:IMG 1237.jpeg
- 02:46, 2 June 2024 Kosar Doraghi talk contribs uploaded File:IMG 1237.jpeg
- 02:41, 2 June 2024 Kosar Doraghi talk contribs created page File:IMG 1226.jpeg
- 02:41, 2 June 2024 Kosar Doraghi talk contribs uploaded File:IMG 1226.jpeg
- 03:20, 1 June 2024 Kosar Doraghi talk contribs created page WINREVAIR (Created page with "{{DrugProjectFormSinglePage |authorTag=Kosar Doraghi, M.D. [mailto:k.doraghi@yahoo.com] |genericName=sotatercept-csrk |aOrAn=an |drugClass=activin signaling inhibitor |indicationType=treatment |indication=adults with pulmonary arterial hypertension (PAH, WHO Group 1) to increase exercise capacity, improve WHO functional class (FC) and reduce the risk of clinical worsening events |hasBlackBoxWarning=Yes |adverseReactions=headache, epistaxis, rash, telangiect...")
- 23:42, 27 May 2024 Jonathan Reyes talk contribs created page Evinacumab-dgnb (Created page with "{{DrugProjectFormSinglePage |authorTag={{JR}} |genericName=evinacumab-dgnb |aOrAn=an |drugClass=angiopoietin-like 3 (ANGPTL3) inhibitor |indicationType=treatment |indication=Evanicumab-dgnb is an angiopoietin-like 3 (ANGPTL3) inhibitor that is FDA approved for the treatment of an adjunct to other low-density lipoproteincholesterol (LDL-C) lowering therapies for the treatment of adult and pediatric patients, aged 5 years and older, with homozygous familial hypercholestero...")
- 22:59, 27 May 2024 Jonathan Reyes talk contribs created page Template:JR (Created page with "Jonathan Reyes, M.D.[jona3098reyes@gmail.com]")
- 14:40, 23 May 2024 Muhammad Waleed talk contribs created page Glofitamab-gxbm (Created page with "{{DrugProjectFormSinglePage |authorTag=Muhammad Waleed, M.B.B.S. [mailto:muhammad_waleed@ymail.com] |genericName=glofitamab. |aOrAn=a |drugClass=bispecific antibodies |indicationType=treatment |indication=COLUMVI (glofitamab) has been approved by the FDA for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS), or large B-cell lymphoma arising from follicular lymphoma aft...")
- 12:43, 23 May 2024 Muhammad Waleed talk contribs created page Rozanolixizumab-noli (Created page with "{{DrugProjectFormSinglePage |authorTag=Muhammad Waleed, M.B.B.S. [mailto:muhammad_waleed@ymail.com] |genericName=Rozanolixizumab-noli (Rystiggo) |aOrAn=a |drugClass=Neonatal Fc receptor blocker |indicationType=treatment |indication=Rystiggo is indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive. |adverseReac...")
- 02:00, 23 May 2024 Kosar Doraghi talk contribs created page Aprocitentan (Created page with "{{DrugProjectFormSinglePage |authorTag=Kosar.Doraghi, M.D.[mailto:k.doraghi@yahoo.com] |genericName=aprocitentan |aOrAn=an |drugClass=endothelin receptor antagonist |indicationType=treatment |indication=hypertension in combination with other antihypertensive drugs, to lower blood pressure in adult patients who are not adequately controlled on other drugs |hasBlackBoxWarning=Yes |adverseReactions=edema/fluid retention and anemia |blackBoxWarningTitle=W...")
- 01:49, 23 May 2024 Kosar Doraghi talk contribs created page File:IMG 1225.jpeg
- 01:49, 23 May 2024 Kosar Doraghi talk contribs uploaded File:IMG 1225.jpeg
- 01:28, 23 May 2024 Kosar Doraghi talk contribs created page File:IMG 1224.jpeg
- 01:28, 23 May 2024 Kosar Doraghi talk contribs uploaded File:IMG 1224.jpeg
- 01:28, 23 May 2024 Kosar Doraghi talk contribs created page File:IMG 1223.jpeg
- 01:28, 23 May 2024 Kosar Doraghi talk contribs uploaded File:IMG 1223.jpeg
- 23:53, 22 May 2024 Alberto Castro Molina talk contribs created page File:Captura de Pantalla 2024-05-18 a la(s) 9.33.11 p.m..png
- 23:53, 22 May 2024 Alberto Castro Molina talk contribs uploaded File:Captura de Pantalla 2024-05-18 a la(s) 9.33.11 p.m..png
- 21:25, 21 May 2024 Alen Antony talk contribs created page Pegunigalsidase alfa-iwxj (Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |genericName=pegunigalsidase alfa-iwxj |indicationType=treatment |indication=Fabry's disease in adults |hasBlackBoxWarning=Yes |adverseReactions=infusion-associated reactions, nasopharyngitis, headache, diarrhea, fatigue, nausea, back pain, pain in extremity, and sinusitis. |blackBoxWarningTitle=HYPERSENSITIVITY REACTIONS including Anaphylaxis |blackBoxWarningBody=Patients may experience hypersensitivity reaction including a...")
- 18:33, 21 May 2024 Rithish Nimmagadda talk contribs created page Vonoprazan, amoxicillin, and clarithromycin (Created page with "{{DrugProjectFormSinglePage |authorTag={{VSRN}} |genericName=vonoprazan, amoxicillin, and clarithromycin |aOrAn=a |drugClass=Potassium-competitive acid blocker |indicationType=treatment |indication=- erosive esophagitis (all grades) and relief of heartburn associated with erosive esophagitis in adults. ,Helicobacter pylori Infection |adverseReactions=-Common adverse reactions (≥2%) with vonoprazan when used for healing of erosive esophagitis: gastritis, diarrhea, abdom...")
- 16:59, 21 May 2024 Rithish Nimmagadda talk contribs created page Pirtobrutinib (Created page with "{{DrugProjectFormSinglePage |authorTag={{VSRN}} |genericName=pirtobrutinib |aOrAn=an |drugClass=noncovalent (reversible) inhibitor of Bruton's tyrosine kinase (BTK). |indicationType=treatment |indication=elapsed or refractory MCL in adults who have received at least 2 lines of prior systemic therapy, including a BTK inhibitor; designated an orphan drug by FDA for treatment of MCL and also in treatment of CLL or SLL in adults who have received at least 2 prior lines of th...")
- 00:09, 21 May 2024 Rithish Nimmagadda talk contribs created page Elacestrant (Created page with "{{DrugProjectFormSinglePage |authorTag={{VSRN}} |genericName=elacestrant |aOrAn=an |drugClass=estrogen receptor antagonist |indicationType=treatment |indication=estrogen receptor (ER)-positive, human epidermal growth factor receptor type 2 (HER2)-negative, estrogen receptor 1 (ESR1)-mutated advanced or metastatic breast cancer that has progressed following ≥1 line of endocrine-based therapy in postmenopausal women or adult men. |fdaLIADAdult=Dosage of elacestrant hydro...")
- 23:07, 20 May 2024 Rithish Nimmagadda talk contribs created page Velmanase alfa-tycv (Created page with "{{DrugProjectFormSinglePage |authorTag={{VSRN}} |genericName=velmanase alfa-tycv |aOrAn=an |drugClass=recombinant preparation of human lysosomal alpha-mannosidase |indicationType=treatment |indication=non-central nervous system manifestations of alpha-mannosidosis in adult and pediatric patients |adverseReactions=Most common adverse reactions (incidence >20%) are hypersensitivity reactions (including anaphylaxis), nasopharyngitis, pyrexia, headache, and arthralgia. |blac...")
- 20:31, 20 May 2024 Rithish Nimmagadda talk contribs created page Retifanlimab-dlwr (Created page with "{{DrugProjectFormSinglePage |authorTag={{VSRN}} |genericName=retifanlimab-dlwr |aOrAn=an |indicationType=treatment |indication=adults with metastatic or recurrent locally advanced Merkel cell carcinoma . Indication approved under accelerated approval based on tumor response rate and duration of response; continued approval may be contingent upon verification and description of clinical benefit in confirmatory trials. |adverseReactions=Adverse effects (≥10%): fatigue...")
- 20:18, 20 May 2024 Rithish Nimmagadda talk contribs created page Tofersen (Created page with "{{DrugProjectFormSinglePage |authorTag={{VSRN}} |genericName=tofersen |aOrAn=an |drugClass=antisense oligonucleotide |indicationType=treatment |indication=amyotrophic lateral sclerosis (ALS) in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene. |adverseReactions=he most common adverse reactions (≥ 10% of patients treated with tofersen and greater than placebo) were pain, fatigue, arthralgia, increased CSF white blood cell, and myalgia. |fdaLIADAdult=...")
- 16:01, 18 May 2024 Rithish Nimmagadda talk contribs created page Ritlecitinib (Created page with "{{DrugProjectFormSinglePage |authorTag={{VSRN}} |genericName=ritlecitinib |aOrAn=a |drugClass=janus kinase 3 (JAK3) inhibitor and also an inhibitor of the tyrosine kinase |indicationType=treatment |indication=severe alopecia areata in adults and adolescents 12 years of age and older |hasBlackBoxWarning=Yes |adverseReactions=Most common adverse reactions (incidence ≥1%) are headache, diarrhea, acne, rash, urticaria, folliculitis, pyrexia, atopic dermatitis, dizziness, i...")
- 17:21, 17 May 2024 Rithish Nimmagadda talk contribs created page Quizartinib (Created page with "{{DrugProjectFormSinglePage |authorTag={{VSRN}} |genericName=quizartinib |aOrAn=a |drugClass=a kinase inhibitor |indicationType=treatment |indication=adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 internal tandem duplication (ITD)-positive as detected by an FDA-approved test. |hasBlackBoxWarning=Yes |adverseReactions=The most common (>20%) adverse reactions, including laboratory abnormalities, are decreased lymphocytes, decreased potassium,...")
- 16:40, 17 May 2024 Rithish Nimmagadda talk contribs created page Lotilaner (Created page with "{{DrugProjectFormSinglePage |authorTag={{VSRN}} |genericName=lotilaner |aOrAn=a |drugClass=gamma-aminobutyric acid (GABA)-gated chloride channel inhibitor |indication=ectoparasiticide (anti-parasitic) indicated for the treatment of Demodex blepharitis |adverseReactions=The most common adverse reaction was instillation site stinging and burning |fdaLIADAdult=still one drop of lotilaner in each eye twice daily (approximately 12 hours apart) for 6 weeks. |fdaLIADPed=Safety...")
- 14:40, 16 May 2024 Alen Antony talk contribs created page Leniolisib (Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |genericName=leniolisib |aOrAn=a |drugClass=kinase inhibitor |indicationType=treatment |indication=activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) in adult and pediatric patients 12 years of age and older. |adverseReactions=headache, sinusitis, and {{atopic dermatitis}}. |brandNames=JOENJA }}")
- 10:11, 16 May 2024 Muhammad Waleed talk contribs created page Avacincaptad pegol (Created page with "{{DrugProjectFormSinglePage |genericName=Avacincaptad Pegol |drugClass=Avacincaptad pegol is a complement C5 protein inhibitor |indication=IZERVAY is indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). |adverseReactions=Common adverse reactions (≥5% of patients) include conjunctival hemorrhage, increased intraocular pressure, and endophthalmitis. |blackBoxWarningTitle=There is no black box warning listed for IZERV...")
- 09:31, 16 May 2024 Muhammad Waleed talk contribs created page File:Talvey (talquetamab-tgvs).png (image for the drug Talvey)
- 09:31, 16 May 2024 Muhammad Waleed talk contribs uploaded File:Talvey (talquetamab-tgvs).png (image for the drug Talvey)
- 07:06, 16 May 2024 Alara E. Dagsali talk contribs created page Diclofenac Patch (Created page with "{{DrugProjectFormSinglePage |authorTag=Alara E.Dagsali |OTC=Yes |genericName=DICLOVIX |indicationType=treatment |indication=Diclofenac sodium topical solution is a nonsteroidal anti-inflammatory drug (NSAID) indicated for the treatment of signs and symptoms of osteoarthritis of the knee(s). |hasBlackBoxWarning=Yes |adverseReactions=Dry Skin (Application Site) Contact Dermatitis (Application Site) Dyspepsia Abdominal Pain Flatulence Pruritus (Application Site) Diarr...")
- 06:42, 16 May 2024 Alara E. Dagsali talk contribs created page Cortisone Acetate (Created page with "{{DrugProjectFormSinglePage |authorTag=Alara E.Dagsali |OTC=Yes |genericName=Cortisone Acetate |aOrAn=a |indicationType=treatment |indication=When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congen...")
- 06:32, 16 May 2024 Alara E. Dagsali talk contribs created page Clocortolone Pivalate (Created page with "{{DrugProjectFormSinglePage |authorTag=Alara E.Dagsali |genericName=Clocortolone Pivalate |indicationType=treatment |indication=Topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. |adverseReactions=The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings. These reactions are listed...")
- 06:20, 16 May 2024 Alara E. Dagsali talk contribs created page Scorpion (Created page with "{{DrugProjectFormSinglePage |genericName=Anascorp |indicationType=treatment |indication=ANASCORP® [centruroides (scorpion) immune F(ab')2 (equine) injection] is an equine-derived antivenom indicated for treatment of patients with clinical signs of scorpion envenomation. |adverseReactions=The most common adverse reactions observed in ≥ 2% of patients in the clinical studies for ANASCORP were: vomiting, pyrexia, rash, nausea and pruritus. |fdaLIADAdult=For Intravenous u...")
- 10:58, 15 May 2024 Alara E. Dagsali talk contribs created page Lodoxamide (Created page with "{{DrugProjectFormSinglePage |authorTag=Alara E.Dagsali |genericName=Alomide |indicationType=treatment |indication=ALOMIDE® (lodoxamide tromethamine ophthalmic solution) 0.1% is indicated in the treatment of the ocular disorders referred to by the terms vernal keratoconjunctivitis, vernal conjunctivitis, and vernal keratitis. |adverseReactions=During clinical studies of ALOMIDE® (lodoxamide tromethamine ophthalmic solution) 0.1%, the most frequently reported ocular adve...")
- 23:48, 13 May 2024 Alen Antony talk contribs created page Fezolinetant (Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |OTC=Yes |genericName=fezolinetant }}")
- 20:38, 13 May 2024 Muhammad Waleed talk contribs created page Talquetamab-tgvs (Created page with "{{DrugProjectFormSinglePage |authorTag=Muhammad Waleed, M.B.B.S. [mailto:muhammad_waleed@ymail.com] |genericName=Talquetamab-tgvs |aOrAn=a |drugClass=bispecific GPRC5D-directed CD3 T-cell engager |indicationType=treatment |indication=TALVEY is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent...")
- 14:50, 13 May 2024 Alen Antony talk contribs created page Nirsevimab-alip (Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |genericName=Nirsevimab-alip |aOrAn=a |drugClass=human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody |indicationType=prevention |indication=Respiratory Syncytial Virus (RSV) lower respiratory tract disease for neonates and infants born during or entering their first RSV season and children up to 24 years of age who are vulnerable to severe RSV disease in their second RSV season. |adverseReactions=rashes and injection...")
- 19:35, 12 May 2024 Kosar Doraghi talk contribs created page File:IMG 1208.jpeg
- 19:35, 12 May 2024 Kosar Doraghi talk contribs uploaded File:IMG 1208.jpeg
- 19:33, 12 May 2024 Kosar Doraghi talk contribs created page File:IMG 1207.jpeg
- 19:33, 12 May 2024 Kosar Doraghi talk contribs uploaded File:IMG 1207.jpeg
- 19:32, 12 May 2024 Kosar Doraghi talk contribs created page File:IMG 1204.jpeg
- 19:32, 12 May 2024 Kosar Doraghi talk contribs uploaded File:IMG 1204.jpeg
_9.33.11_p.m..png){kind=link}
.png){kind=link}
